monoclon
antibodi
mab
among
fastestgrow
therapeut
develop
broad
rang
indic
includ
neutral
toxin
bacteria
virus
nevertheless
mab
potenc
still
rel
low
compar
convent
polyclon
ab
prepar
moreov
efficaci
individu
neutral
mab
may
significantli
hamper
potenti
absenc
modif
target
epitop
mutant
subtyp
infecti
agent
limit
individu
neutral
mab
overcom
use
oligoclon
combin
sever
mab
differ
specif
target
antigen
studi
conduct
lab
other
show
combin
mab
prepar
may
present
substanti
synergi
potenc
calcul
addit
potenc
individu
mab
compon
moreov
oligoclon
prepar
expect
better
suit
compens
reduc
efficaci
due
epitop
variat
review
synergist
neutral
properti
combin
oligoclon
ab
prepar
describ
effect
ab
affin
autolog
fc
fraction
target
critic
number
epitop
well
unexpect
contribut
nonneutr
clone
synergist
neutral
effect
present
discuss
sinc
emerg
hybridoma
technolog
research
develop
monoclon
antibodi
mab
rapidli
progress
mab
wellcharacter
individu
full
partial
immunoglobulin
molecul
current
develop
broad
rang
indic
diagnost
imag
treatment
medic
condit
cancer
infecti
diseas
recent
year
mab
relat
product
fastest
grow
class
therapeut
agent
use
antibodi
therapeut
conceiv
long
develop
mab
technolog
passiv
immun
ie
transfer
antibodi
serum
immun
person
anim
nonimmun
one
first
demonstr
year
ago
pioneer
experi
behr
kitasato
serum
therapi
protect
diphtheria
serum
therapi
commonli
use
treat
infecti
diseas
discoveri
chemotherapi
form
sulfonamid
antibiot
less
expens
difficult
use
significantli
fewer
advers
effect
pathogenspecif
render
diagnosi
microbi
infect
unnecessari
treatment
thu
serum
therapi
push
asid
howev
emerg
multidrugresist
form
new
old
pathogen
recent
explos
immunocompromis
popul
worldwid
led
necessari
resurg
develop
antibodybas
therapeut
treat
prevent
new
wave
drugresist
infecti
diseas
furthermor
wherea
antimicrobi
drug
kill
microb
erad
preform
toxin
specif
antibodi
compound
neutral
given
toxin
therefor
antibodi
remain
attract
therapeut
purpos
howev
modern
polyclon
antibodi
pab
base
therapeut
although
improv
compar
past
serum
therapi
continu
suffer
major
limit
might
elegantli
overcom
mabbas
prepar
first
treatment
hyperimmun
equineor
animalderiv
antisera
associ
substanti
side
effect
includ
hypersensitivityrel
reaction
serum
sick
anaphylaxi
addit
use
human
antisera
involv
risk
bloodborn
diseas
safeti
limit
address
use
humanderiv
human
mabbas
prepar
display
substanti
decreas
incid
side
effect
viral
contamin
human
replac
mous
constant
region
variabl
framework
human
sequenc
result
product
display
significantli
reduc
immunogen
improv
vivo
toler
human
human
mab
exhibit
enhanc
pharmacokinet
enabl
administr
lower
protein
load
reduc
frequenc
administr
cours
treatment
second
pabbas
prepar
exhibit
signific
batchtobatch
variabl
suppli
limit
contrast
mab
produc
vitro
therebi
ensur
unlimit
suppli
highli
purifi
wellcharacter
product
devoid
contamin
protein
despit
potenti
mab
power
tool
field
infecti
diseas
toxin
past
year
follow
hybridoma
revolut
immunoglobulin
igg
deriv
approv
use
variou
indic
one
mab
approv
prevent
viral
infect
rsv
one
mab
approv
us
treatment
bacteri
toxin
anthrax
other
clinic
design
treatment
cancer
autoimmun
allerg
condit
although
mani
mab
purifi
character
protect
efficaci
differ
toxin
investig
clinic
trial
pab
remain
almost
avail
prepar
indic
mabbas
therapi
limit
first
mab
exhibit
unpreced
specif
antigen
target
extrem
specif
may
hamper
efficaci
individu
mab
case
absenc
modif
target
epitop
mutant
subtyp
infecti
agent
second
potenc
mab
especi
play
role
neutral
pathogen
toxin
remain
rel
low
compar
pabbas
prepar
inferior
neutral
potenc
individu
mab
may
attribut
differ
function
impact
specif
antigen
epitop
low
affin
target
epitop
biochem
stabil
mab
molecul
reduc
clearanc
mabantigen
immunecomplex
ic
two
major
limit
individu
mabbas
prepar
low
neutral
potenc
potenti
failur
treat
mutant
subtyp
overcom
combin
sever
mab
form
mab
cocktail
moreov
discuss
detail
recent
studi
show
mab
cocktail
exhibit
synergist
neutral
ie
mab
cocktail
display
substanti
elev
neutral
activ
exce
level
improv
expect
contribut
mab
mixtur
fact
neutral
activ
mab
cocktail
similar
potenc
pabbas
prepar
phenomenon
demonstr
lab
well
gener
mab
botulinum
neurotoxin
bont
simultan
obtain
neutral
mab
differ
bont
singl
autom
process
also
success
demonstr
signific
synergist
neutral
combin
antibont
mab
bont
serv
excel
model
complex
antigen
mab
requir
produc
clostridium
botulinum
strain
consid
lethal
toxin
identifi
estim
human
median
lethal
dose
ngkg
bodi
weight
bont
toxin
classifi
cdc
categori
agent
howev
standard
treatment
botul
reli
equin
limit
amount
human
pabbas
antitoxin
therapi
togeth
support
care
thu
need
safe
reliabl
antibont
mabbas
pharmaceut
drug
review
describ
mechan
underli
neutral
synergi
oligoclonalbas
prepar
emphasi
biolog
toxin
import
ab
affin
molecular
structur
igg
involv
mabantigen
ic
clearanc
unexpect
contribut
individu
nonneutr
mab
synergist
neutral
effect
discuss
natur
human
polyclon
respons
elicit
concert
action
antibodi
display
multipl
specif
bind
sever
epitop
use
care
assembl
cocktail
consist
recombin
human
mab
might
expect
mechan
would
effici
recruit
use
singl
mab
concept
combin
sever
mab
increas
therapeut
efficaci
overcom
limit
pab
appear
logic
inde
last
year
mani
studi
evalu
two
mab
variou
combin
improv
efficaci
potenti
therapeut
infecti
diseas
primarili
virus
toxin
see
tabl
list
oligoclon
antibodybas
prepar
variou
toxin
mab
combin
exert
addit
synergist
neutral
effect
demonstr
potenti
valu
futur
therapi
combin
two
drug
antitoxin
mab
four
outcom
expect
addit
effect
ie
summat
individu
neutral
activ
antagon
defin
reduct
efficaci
indiffer
ie
one
drug
enhanc
reduc
efficaci
second
drug
synerg
protect
properti
combin
mab
prepar
significantli
exceed
addit
effect
compon
mixtur
attempt
estim
combin
effect
multipl
drug
document
centuri
chou
talalay
propos
gener
diagnost
function
determin
applic
experiment
data
distinguish
mutual
exclus
nonexclus
drug
provid
equat
analyz
quantifi
synerg
summat
antagon
multipl
drug
author
design
combin
index
ci
valu
indic
synerg
addit
effect
summat
antagon
respect
drug
combin
similarli
pohl
et
al
appli
fraction
inhibitori
concentr
fic
indic
approach
evalu
drug
combin
character
interact
among
multipl
mab
similar
ci
interact
two
mab
consid
synergist
fic
index
addit
fic
index
equal
indiffer
fic
index
antagonist
fic
index
synergist
drug
combin
facilit
reduct
drug
dose
maintain
efficaci
foldreduct
dose
drug
includ
synergist
combin
given
effect
level
compar
dose
drug
alon
calcul
dose
reduct
index
dri
ci
dri
also
enabl
use
comparison
extent
efficaci
enhanc
neutral
mab
combin
differ
studi
although
mani
studi
involv
mab
cocktail
provid
direct
data
regard
valu
studi
tabl
enhanc
neutral
mab
combin
detect
compar
individu
mab
compon
enhanc
often
refer
synerg
author
howev
although
enhanc
neutral
effect
report
difficult
compar
extent
synergi
among
differ
studi
due
variou
factor
includ
toxin
biolog
natur
neutral
assay
conduct
either
vivo
instanc
mous
protect
assay
vitro
cell
toxic
assay
use
differ
cell
type
thu
inform
tabl
estim
care
analysi
light
foldenhanc
terminolog
select
describ
superior
mab
combin
compar
compon
case
infer
differ
neutral
applic
previou
studi
conduct
lab
specif
monoclon
antibodi
three
botulinum
serotyp
b
e
gener
immun
mice
trival
mixtur
recombin
ctermin
half
heavi
chain
hc
botulinum
neurotoxin
b
e
follow
immun
conduct
parallel
differenti
robot
hybridoma
screen
identifi
specif
mab
three
toxin
integr
autom
robot
liquidhandl
system
significantli
improv
overal
screen
capac
hybridoma
within
serotypespecif
group
produc
neutral
mab
major
protect
toxin
dose
mous
lethal
dose
encourag
result
sought
determin
whether
mab
combin
serotypespecif
group
exhibit
increas
neutral
activ
best
combin
antiserotyp
e
mab
display
high
synergist
neutral
activ
compon
figur
cocktail
antiserotyp
mab
protect
toxin
improv
calcul
addit
effect
mixtur
compon
strikingli
remov
three
nonneutr
mab
antibonta
cocktail
dramat
reduc
neutral
activ
import
nonneutr
individu
mab
also
demonstr
antib
mab
confirm
addit
singl
nonneutr
mab
neutral
antibodi
may
induc
synerg
other
also
found
combin
seven
appar
nonneutr
mab
one
neutral
mab
direct
heavi
chain
tetanu
neurotoxin
tent
induc
synergist
neutral
induct
synergist
neutral
effect
combin
nonneutr
mab
critic
comprehens
mechan
underli
synerg
may
import
consequ
futur
screen
select
potent
neutral
mab
cocktail
mechan
underli
antibodymedi
synergi
toxin
neutral
depend
least
part
function
neutral
epitop
recogn
antibodi
interfer
interact
toxin
target
cell
bind
affin
antibodi
qualiti
antibodytoxin
complex
clearanc
bloodstream
accordingli
induct
neutral
synerg
might
explain
least
three
put
mechan
first
simultan
bind
interf
mab
multipl
function
site
toxin
second
increas
affin
mixtur
mab
compar
mab
compon
third
enhanc
fcmediat
clearanc
antibodytoxin
complex
serum
due
multimer
antibodi
decor
toxin
three
mechanist
explan
synergi
may
exert
partial
influenc
differ
mab
combin
may
consid
differ
aspect
tripartit
phenomenon
togeth
three
mechan
may
induc
synergist
neutral
humor
respons
evad
pathogen
involv
seri
effector
mechan
antibodi
includ
direct
bind
specif
epitop
indirect
antibodymedi
event
primarili
consist
antibodydepend
cellular
cytotox
adcc
antibodydepend
cell
phagocytosi
adcp
complementdepend
cytotox
cdc
centuri
toxin
believ
neutral
antibodi
indirect
mediat
measur
rather
direct
interf
antibodydepend
mechan
antibodi
bind
toxin
interfer
interact
host
cell
thu
prevent
attach
toxin
target
cell
enzymat
activ
might
otherwis
damag
target
cell
theoret
antibodi
interfer
toxin
variabl
region
antibodi
requir
moieti
specif
recogn
bind
epitop
target
toxin
thu
bind
alon
gener
consid
neutral
constant
region
fc
antibodi
known
exert
effector
function
adcc
adcp
cdc
thought
becom
activ
bacteria
tumor
cell
involv
mechan
humor
antitoxin
respons
unclear
altern
role
fc
clearanc
ic
antibodi
pharmacokinet
discuss
section
toxin
neutral
consid
primarili
due
bind
ab
toxin
block
activ
design
combin
mab
mimic
polyclon
respons
princip
rational
would
select
mab
bind
distinct
nonoverlap
epitop
combin
may
facilit
bind
multipl
igg
molecul
target
toxin
thu
potenti
block
variou
essenti
function
domain
simultan
blockad
increas
probabl
mab
interfer
interact
toxin
target
cell
ultim
result
either
addit
synergist
neutral
demonstr
particular
domain
differ
toxin
associ
enhanc
neutral
depend
structur
mechan
action
instanc
hc
kda
consid
receptor
bind
domain
bont
target
neuron
wherea
ntermin
region
hn
serv
transloc
domain
catalyt
domain
zinc
endopeptidas
local
light
chain
l
surfac
residu
hc
vari
dramat
among
differ
bont
serotyp
hc
fragment
nontox
neutral
epitop
map
domain
neutral
epitoperich
hc
use
subunit
vaccin
produc
neutral
antibodi
bont
bacillu
anthraci
caus
agent
anthrax
exert
toxic
via
dissemin
tripartit
exotoxin
compos
protect
antigen
pa
lethal
factor
lf
edema
factor
ef
pa
play
critic
role
anthrax
pathogenesi
associ
either
lf
form
lethal
toxin
letx
ef
form
edema
toxin
edtx
vaccin
compos
pa
show
pabind
antibodi
effect
limit
b
anthraci
pathogen
moreov
demonstr
pa
lf
bind
specif
protect
epitop
requir
neutral
pertussi
primarili
toxinmedi
diseas
caus
bordetella
pertussi
pertussi
toxin
ptx
major
virul
factor
chemic
genet
detoxifi
ptx
major
compon
acellular
vaccin
formul
combin
four
addit
virul
factor
shown
ptxneutral
ab
bind
subunit
necessari
transloc
cytoplasm
endocytosi
respect
ricin
molecular
weight
rel
simpl
toxin
consist
enzymat
subunit
rta
bind
b
subunit
rtb
join
disulfid
bond
ohara
et
al
found
epitop
specif
primari
determin
abil
antibodi
neutral
ricin
specif
epitop
interfer
enzymat
activ
rta
moreov
neutral
mab
primarili
direct
situat
within
rta
fold
domain
wherea
nonneutr
mab
target
random
loop
coil
larg
local
domain
rare
case
singl
mab
protect
pabbas
prepar
via
blockad
pivot
epitop
result
complet
neutral
evid
exist
hot
spot
epitop
display
uniqu
function
impact
suggest
interf
one
epitop
might
highli
benefici
toxin
neutral
report
neutral
mab
potenc
individu
mab
substanti
lower
pab
variou
studi
report
potenc
protect
mab
augment
addit
synergist
via
addit
protect
mab
combin
protect
mab
target
differ
epitop
toxin
molecul
synerg
protect
efficaci
howev
exact
mechan
underli
synergist
rather
mere
addit
neutral
follow
blockad
multipl
signific
epitop
fulli
understood
synergi
may
stem
interfer
two
epitop
although
essenti
individu
vital
combin
concurr
blockad
type
epitop
might
synergist
shut
essenti
function
pathway
toxin
bind
receptor
target
phenomenon
expect
promin
import
neutral
epitop
perform
redund
function
bind
cellular
receptor
cleav
target
substrat
etc
figur
follow
find
support
possibl
schemat
illustr
simultan
interfer
multipl
function
epitop
synergist
neutral
effect
may
result
antibodi
interfer
two
distinct
epitop
although
essenti
individu
vital
combin
b
import
function
pathway
toxin
bind
receptor
target
might
elimin
concurr
blockad
abbrevi
use
eepitop
rreceptor
target
cell
bont
two
class
bind
site
exist
protein
gangliosid
receptor
resid
hc
domain
thu
doublereceptor
concept
preval
studi
chen
et
al
predict
two
mab
recogn
protein
gangliosid
receptor
bind
domain
respect
synergist
neutral
bont
studi
investig
select
three
neutral
mab
recogn
differ
nonoverlap
epitop
bontb
compar
neutral
effect
variou
antibodi
combin
found
mab
respond
gangliosid
receptor
bind
site
synerg
two
mab
recogn
nonoverlap
epitop
syt
ii
protein
receptor
howev
combin
latter
two
mab
exert
synergist
effect
exampl
demonstr
combin
two
mab
recogn
distinct
function
domain
bont
may
repres
gener
principl
potent
synergist
effect
interestingli
chen
et
al
analyz
result
gener
lab
jame
mark
develop
mab
bonta
found
neutral
potenc
one
pair
mab
bind
transloc
domain
sialogangliosid
bind
domain
respect
time
higher
anoth
pair
whose
epitop
locat
function
domain
find
provid
addit
evid
combin
mab
recogn
differ
function
domain
like
synerg
combin
mab
recogn
function
domain
rtb
subunit
ricin
contain
two
galactos
bind
site
function
independ
distant
one
anoth
hu
et
al
gener
four
mab
direct
rtb
subunit
found
bound
conform
epitop
high
affin
test
pair
mab
demonstr
synergist
neutral
ricin
vitro
vivo
hu
et
al
hypothes
two
rtb
domain
homolog
structur
similar
singl
rtbspecif
mab
may
block
galactos
bind
pocket
bind
similar
conform
epitop
share
domain
simultan
bind
two
mab
like
synergist
interfer
ricin
attach
cell
addit
author
specul
mab
might
bind
domain
interrupt
transport
rta
er
cytosol
also
determin
synergist
effect
mab
pair
depend
differ
ricin
neutral
activ
relat
epitop
specif
ricinbind
affin
relat
antibodi
isotyp
anoth
ricin
studi
mcguiness
et
al
identifi
character
murin
antirtb
mab
use
vero
cell
cytotox
assay
compar
known
antirta
mab
found
approxim
twofold
effect
neutral
ricin
investig
studi
mechan
action
two
mab
found
block
ricin
attach
galactosid
receptor
although
direct
rta
activ
tent
close
rel
bont
dichain
toxin
light
chain
lc
heavi
chain
hc
link
singl
disulfid
bond
kda
lc
act
zincdepend
endopeptidas
kda
hc
compos
two
distinct
function
domain
transloc
domain
ntermin
half
neuron
gangliosid
bind
domain
ctermin
half
similar
bont
accept
tent
act
via
dual
receptor
model
gangliosid
glycosyl
protein
synapt
vesicl
protein
involv
one
pioneer
studi
mab
combin
toxin
volk
et
al
evalu
effect
mab
differ
tent
subunit
found
neutral
mab
bound
epitop
hc
tent
approxim
half
ctermin
region
half
ntermin
region
combin
mab
found
differ
cocktail
mab
exert
synergist
neutral
vivo
result
greater
protect
individu
neutral
mab
author
hypothes
larg
number
epitop
found
involv
neutral
suggest
differ
antibodi
block
distinct
step
toxin
function
simultan
bind
multipl
epitop
requir
neutral
synergist
oligoclon
antibodi
interfer
may
necessarili
associ
known
neutral
epitop
may
rather
base
either
adher
epitop
individu
play
appar
role
togeth
perform
signific
function
blockad
function
epitop
due
steric
hindranc
caus
valenc
nearbi
bound
antibodi
instanc
cheng
et
al
demonstr
combin
two
mab
one
direct
lc
catalyt
domain
bonta
direct
transloc
domain
inhibit
endopeptidas
activ
instead
block
toxin
entri
primari
cultur
neuron
cell
synergist
manner
author
suggest
via
steric
hindranc
mab
may
interf
bonta
receptor
bind
subsequ
neuron
intern
interact
intracellular
similarli
synergist
effect
combin
protect
nonprotect
mab
demonstr
pair
protect
mab
diseaseenhanc
mab
anthrax
lab
arturo
casadeval
chow
et
al
investig
whether
combin
protect
diseaseenhanc
mab
act
concert
abrog
pa
oligomer
thu
prevent
transloc
lf
ef
cell
caus
subsequ
toxic
individu
protect
mab
inhibit
furin
cleavag
subsequ
oligom
format
wherea
enhanc
mab
opposit
howev
igg
mab
combin
result
mabpa
complex
format
complet
abolish
pa
oligomer
via
furin
cleavageindepend
mechan
evid
support
concept
synergist
activ
partial
deriv
combin
mab
simultan
block
differ
function
epitop
provid
neutral
staphylococc
enterotoxin
b
seb
one
sever
potent
exotoxin
secret
staphylococcu
aureu
caus
toxic
shock
syndrom
tss
similar
superantigen
seb
simultan
bind
major
histocompat
complex
class
ii
mhcii
molecul
antigenpres
cell
apc
tcell
receptor
tcr
incorpor
v
chain
block
antibodi
may
prevent
seb
facilit
format
mhciisebtcr
complex
therebi
inhibit
toxin
accord
crystal
structur
complex
consist
seb
mhcii
tcr
two
bind
site
spatial
distinct
contact
area
varshney
et
al
gener
mab
seb
evalu
differ
pair
mab
one
none
mab
individu
protect
seb
toxic
author
report
protect
achiev
mab
combin
administ
simultan
fact
first
report
enhanc
protect
sebinduc
lethal
shock
sebil
demonstr
mice
combin
two
individu
nonneutr
mab
mab
recogn
noncontinu
residu
like
contribut
conform
epitop
phenomenon
synergist
neutral
due
blockad
function
nonoverlap
epitop
restrict
toxin
also
demonstr
studi
virus
bacteria
li
et
al
evalu
differ
combin
human
mab
direct
variou
epitop
human
immunodefici
viru
type
envelop
glycoprotein
abil
neutral
chimer
simianhuman
immunodefici
viru
accord
put
synergist
mechan
potent
neutral
tripl
combin
evalu
attain
use
three
mab
direct
three
differ
domain
one
author
evalu
combin
four
mab
previou
three
mab
one
recogn
bind
site
found
higher
neutral
potenc
higher
degre
synergi
tripl
combin
similarli
meulen
et
al
present
experiment
anim
data
show
protect
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
feasibl
use
mixtur
two
human
mab
mab
combin
neutral
sarscov
synergist
manner
recogn
differ
epitop
receptorbind
domain
faleri
et
al
recent
report
function
character
two
mab
recogn
factor
h
bind
protein
fhbp
neisseria
meningitidi
serogroup
b
menb
surfac
fhbp
prove
virul
factor
n
meningitidi
target
function
bactericid
antibodi
fhbp
bind
human
factor
h
hfh
serv
downregul
host
altern
complement
pathway
help
organ
evad
host
innat
immun
although
mab
recogn
two
overlap
epitop
part
hfh
bind
site
nterminu
hfbp
elicit
complement
mediat
bactericid
activ
menb
test
either
individu
combin
interestingli
test
combin
anoth
mab
recogn
conform
epitop
locat
cterminusopposit
hfh
bind
site
two
mab
combin
exert
differ
level
synergist
activ
depend
orient
mab
fhbp
author
suspect
concomit
bind
one
combin
may
result
reciproc
orient
suitabl
correct
engag
rel
posit
combin
might
optim
promot
effect
summari
combin
mab
bind
function
distinct
epitop
toxin
may
result
synergist
neutral
moreov
even
combin
mab
individu
display
neutral
activ
may
exert
synergist
neutral
effect
due
either
steric
hindranc
adjac
neutral
epitop
partial
full
epitop
redund
overcom
simultan
bind
anoth
mechan
may
underli
synergist
neutral
activ
mab
combin
increas
affin
cocktail
compar
mab
compon
variou
find
indic
neutral
potenc
associ
affin
antibodi
toxin
demonstr
follow
section
addit
find
indic
simultan
bind
multipl
mab
multisit
antigen
may
result
substanti
increas
overal
affin
taken
togeth
find
suggest
certain
combin
mab
bind
toxin
much
strongli
mab
alon
thu
induc
synergist
neutral
correl
antibodi
bind
affin
toxin
neutral
somewhat
intuit
toxin
block
subsequ
clearanc
form
ic
depend
bind
antibodi
toxin
thu
one
easili
conceiv
adher
toxin
would
efficaci
bind
antibodi
epitop
stronger
thu
prolong
durat
epitop
occupi
lead
potent
inhibit
clearanc
bloodstream
sever
indic
neutral
activ
antibodi
associ
affin
target
epitop
inde
vivo
assay
conduct
lab
reveal
neutral
potenc
mab
three
differ
bont
associ
increas
affin
toxin
neutral
mab
exhibit
highest
antitoxin
elisa
titer
pless
et
al
also
report
common
characterist
antibontahc
neutral
mab
examin
high
affin
anoth
antibont
studi
amersdorf
et
al
show
potent
antihc
scfv
display
highest
affin
epitop
accord
concept
maynard
et
al
show
protect
anthrax
toxin
recombin
antibodi
fragment
correl
antigen
affin
likewis
scott
character
panel
antitetanu
toxin
scfv
found
clone
neutral
toxin
activ
base
gangliosid
bind
assay
effect
strongli
relat
affin
clone
nevertheless
found
mab
exhibit
neutral
activ
despit
display
high
elisa
titer
result
suggest
high
affin
may
necessari
suffici
paramet
neutral
potenc
find
describ
previou
section
demonstr
affin
antibodi
epitop
correl
neutral
activ
thu
simultan
bind
multipl
mab
increas
overal
affin
mab
antigen
neutral
activ
combin
mab
may
enhanc
overal
affin
increas
affin
measur
strength
noncoval
interact
antibodi
antigen
mathemat
repres
equilibrium
constant
k
character
revers
bind
antibodi
epitop
antigen
affin
divid
intrins
function
term
intrins
affin
character
system
involv
monoval
interact
one
paratop
one
epitop
term
function
affin
also
known
avid
refer
higher
order
complex
bival
multival
ab
number
bind
site
per
antigen
reflect
intrins
affin
valenc
topolog
relationship
antigen
determin
antibodi
combin
site
strength
multival
interact
function
affin
avid
usual
exce
sometim
greatli
correspond
intrins
affin
multival
linkag
within
ic
form
either
epitop
express
separ
antigen
ab
molecul
specif
mab
divers
epitop
ab
two
specif
case
natur
immun
reaction
may
cooper
interact
eventu
lead
increas
function
affin
two
basic
mechan
may
underli
cooper
interact
mab
bind
divers
epitop
first
bind
one
bival
mab
two
epitop
two
solubl
antigen
therebi
facilit
crosslink
increas
probabl
second
mab
specif
independ
epitop
could
bind
two
site
instead
one
site
phenomenon
demonstr
year
ago
moyl
et
al
antibodi
human
chorion
gonadotropin
hcg
author
found
mab
pair
other
display
higher
affin
hormon
either
mab
alon
increas
affin
associ
format
stabl
circular
complex
consist
two
antibodi
molecul
one
two
mab
two
hcg
molecul
second
increas
function
affin
observ
multipl
mab
may
due
conform
chang
antigen
occur
upon
bind
first
mab
result
higher
affin
second
third
mab
illustr
figur
thu
bind
first
antibodi
might
induc
stabl
conform
antigen
thermodynam
entrop
favor
bind
subsequ
antibodi
evid
support
influenc
affin
synergist
neutral
toxin
recent
report
tetanu
studi
scott
et
al
character
scfv
tent
found
certain
scfv
combin
exhibit
synergist
bind
base
competit
bind
studi
find
agre
result
scfv
reduc
toxin
activ
without
recogn
hc
domain
known
attach
gangliosid
thu
author
suggest
synergi
bind
stem
conform
chang
toxin
upon
bind
one
scfv
favor
bind
next
target
epitop
may
less
import
identifi
toxinneutr
mab
accord
find
yousefi
et
al
detect
synergist
neutral
effect
one
pair
mab
pair
recogn
two
distinct
close
overlap
epitop
within
fragment
tent
pair
mab
display
vivo
potenc
sever
time
higher
commerci
tig
antibodi
prepar
author
specul
observ
cooper
bind
effect
caus
conform
chang
tent
protein
bind
first
antibodi
thermodynam
facilit
bind
second
antibodi
ngundi
et
al
investig
mechan
involv
synergist
neutral
effect
combin
antipa
mab
anthrax
author
found
one
mab
promot
bival
bind
anoth
mab
pa
presum
bridg
two
pa
monom
propos
bridg
via
one
mab
promot
bridg
via
thu
transient
dissoci
one
antibodi
arm
toxin
would
result
rapid
rebind
antibodi
bridg
would
prevent
antigen
diffus
away
phenomenon
would
substanti
increas
antibodi
avid
ie
combin
strength
multipl
bond
interact
result
synergist
neutral
evid
describ
suggest
increas
affin
mab
cocktail
might
result
synergist
enhanc
toxin
neutral
lowaffin
fcr
bind
monomer
immunoglobulin
detect
affin
nevertheless
bind
aggreg
antibodi
complex
multival
antigen
high
avid
thu
multival
fcdecor
antigen
effici
recogn
basi
effect
clearanc
ic
rather
unbound
antibodi
monomer
antibodyantigen
ic
low
affin
fcr
resid
macrophag
may
relev
high
affin
fcr
respect
clearanc
ic
human
liver
low
affin
detect
kupffer
cell
liver
sinusoid
endotheli
cell
wherea
high
affin
express
liver
macrophag
addit
demonstr
rate
remov
complex
liver
proport
size
complex
consequ
adher
individu
mab
antigen
toxin
would
expect
form
rel
small
ic
one
antigen
molecul
bind
one
mab
except
rare
instanc
involv
repetit
epitop
larger
iggtoxin
ic
much
effici
clear
bloodstream
anticip
combin
two
mab
bind
distinct
toxin
epitop
thu
mimick
polyclon
reaction
larger
ic
form
clearanc
combin
neutral
mab
substanti
enhanc
thu
toxin
clearanc
consid
much
effect
mab
combin
singl
mab
treatment
ic
form
solubl
igg
bind
target
antigen
ic
directli
administ
nonimmun
anim
form
follow
administr
low
dose
antigen
immun
anim
remov
rapidli
part
reticuloendotheli
system
fix
mononuclear
phagocyt
system
certain
circul
leukocyt
express
receptor
ic
gener
clearanc
ic
follow
polyclon
respons
occur
via
two
pathway
involv
antibodi
fc
one
clear
mechan
mediat
bind
second
mechan
mediat
complement
system
play
crucial
role
ic
handl
two
mechan
act
independ
thu
antibodi
fcmediat
clearanc
thought
play
import
role
toxin
neutral
well
accordingli
demonstr
associ
pab
bont
lead
enhanc
clearanc
circul
rat
particularli
liver
spleen
notabl
role
igg
fc
might
obscur
involv
toxinigg
ic
clearanc
instanc
fc
substanti
contribut
igg
stabil
bloodstream
primarili
due
protect
neonat
fcr
fcrn
fcrn
play
critic
role
regul
level
circul
igg
rodent
higher
speci
via
strict
phdepend
iggfcrn
bind
fcrnbound
antibodi
thought
protect
degrad
therebi
increas
halflif
igg
serum
therefor
use
antitoxin
agent
bear
fc
fab
scfv
etc
thu
display
shorter
halflif
intact
igg
would
expect
exhibit
reduc
efficaci
due
rapid
decreas
concentr
antitoxin
agent
bloodstream
demonstr
bont
toxic
studi
nevertheless
addit
inferior
potenc
f
ab
antitoxin
mazuet
et
al
show
spite
shorter
halflif
one
f
ab
retain
neutral
efficaci
compar
intact
igg
interestingli
mab
affect
fc
delet
display
much
higher
affin
mab
elimin
foreign
fc
equin
antitoxin
prepar
serv
lower
immunogen
nevertheless
polyclon
f
ab
prepar
protect
toxin
challeng
without
activ
fcmediat
effector
function
protect
suggest
high
dose
f
ab
may
compens
lack
fcmediat
mechan
may
induc
neutral
sole
via
toxin
block
furthermor
plausibl
addit
human
fc
fragment
equin
f
ab
prepar
would
improv
antitoxin
efficaci
reduc
total
amount
foreign
protein
administ
patient
howev
manipul
applic
polyclon
prepar
may
difficult
evalu
anim
model
due
varianc
complement
receptor
cr
among
speci
manipul
fc
fragment
perform
mab
enabl
examin
role
fc
neutral
vivo
recent
gener
character
mous
lack
murin
describ
model
may
enabl
accur
predict
consequ
link
human
igg
particular
biolog
respons
recapitul
humanspecif
express
pattern
mous
model
use
recent
assess
activ
antianthrax
toxin
mab
contain
specif
fc
variant
select
enhanc
affin
particular
human
accumul
evid
recent
year
support
involv
igg
fc
mab
pab
toxin
neutral
vital
et
al
show
f
ab
fragment
antipa
mab
less
potent
complet
igg
neutral
anthrax
toxin
vitro
even
though
retain
equival
affin
pa
addit
fcrblock
antibodi
greatli
reduc
activ
mab
neutral
activ
mous
rabbit
human
antisera
elicit
pa
vaccin
effect
abrog
block
fcr
howev
vivo
significantli
higher
concentr
f
ab
protect
anthrax
toxin
cytotox
thu
vivo
protect
unambigu
attribut
fcenhanc
neutral
activ
unclear
whether
potenc
reduct
vivo
also
attribut
shorter
halflif
f
ab
fragment
neutral
activ
abrog
fcr
blocker
pab
mab
treatment
impli
potenc
inde
fcrdepend
experi
conduct
arturo
casadeval
colleagu
broaden
understand
function
fc
antipa
antibodi
abboud
et
al
gener
ident
variabl
region
specif
variant
antipa
mab
found
efficaci
antibodymedi
neutral
depend
isotyp
neutral
activ
requir
compet
furthermor
show
mab
prevent
lethal
toxin
cytotox
effici
mab
passiv
immun
mab
protect
wildtyp
mice
b
anthraci
infect
nevertheless
precis
toxin
neutral
mechan
engag
unclear
author
hypothes
mab
ic
endocytos
sort
lysosom
degrad
suggest
differ
efficaci
isotyp
impli
differ
fcmediat
effector
function
rather
defect
endocytosi
mice
defici
function
fc
also
evalu
use
antitoxin
system
akiyoshi
et
al
evalu
mab
direct
b
subunit
shiga
toxin
primari
virul
factor
hemolyt
urem
syndrom
hu
investig
gener
evalu
vitro
vivo
isotyp
variant
fab
f
ab
fragment
mab
specif
subunit
isotyp
variant
exhibit
protect
vitro
variant
exhibit
highest
protect
vivo
although
fab
f
ab
fragment
exhibit
protect
vitro
exhibit
protect
vivo
author
obtain
similar
result
mab
direct
b
subunit
pincu
et
al
examin
role
fc
region
mediat
protect
ricin
toxic
found
compar
result
compar
vitro
vivo
effect
intact
ig
fab
fragment
deriv
pab
antia
chain
mab
prepar
result
reveal
littl
differ
ig
fab
term
antigen
bind
vitro
neutral
hela
cell
found
rel
larg
differ
protect
anim
addit
vivo
experi
demonstr
murin
mab
protect
strongli
chimer
mousehuman
variant
indic
mous
fc
region
perform
better
human
fc
mice
moreov
investig
explor
role
protect
cell
ricin
toxic
use
panel
heladeriv
cell
carri
fcr
human
found
presenc
absenc
fcr
influenc
mabmedi
protect
find
indic
neither
fc
region
presenc
fcr
target
cell
influenc
abmedi
protect
individu
cell
howev
vivo
presenc
fc
enhanc
protect
efficaci
varshney
et
al
compar
neutral
protect
activ
antiseb
mab
vitro
vivo
author
demonstr
chang
isotyp
alreadi
protect
mab
without
affect
antigen
specif
sensit
enhanc
protect
abil
suggest
therapeut
role
fc
directli
determin
role
fc
recent
measur
protect
properti
igg
mab
f
ab
form
mice
expos
bonta
equal
amount
igg
mab
f
ab
fragment
pmolmous
incub
increas
amount
bonta
rang
mixtur
inject
mice
surviv
monitor
intact
igg
mab
protect
mice
challeng
bonta
wherea
f
ab
fragment
protect
toxin
thu
protect
efficaci
f
ab
mice
lower
igg
form
demonstr
import
role
fc
protect
bont
toxic
paper
prepar
recent
sever
studi
conduct
lab
charl
shoemak
directli
investig
phenomenon
synergist
neutral
mediat
increas
fc
valenc
illustr
figur
sepuldeva
et
al
propos
novel
concept
bont
neutral
exert
combin
highaffin
epitopetag
scfv
bonta
serv
block
arm
antitag
mab
contain
fc
serv
clear
fc
arm
manner
investig
elegantli
illumin
critic
contribut
fcmediat
clearanc
bont
synergist
neutral
dissect
function
fc
put
mechan
author
show
individu
nonneutr
scfv
addit
addit
clear
fc
synergist
increas
level
protect
bonta
thu
scfv
contain
two
copi
tag
ie
two
clear
fc
block
arm
instead
one
protect
toxin
approxim
enhanc
approxim
foldchang
addit
differ
scfv
improv
achiev
inclus
addit
tag
like
result
fc
decor
toxin
follow
studi
definit
role
fcmediat
clearanc
synergist
activ
demonstr
pharmacokinet
studi
show
bonta
rapidli
clear
sera
mice
administ
pool
antibonta
scfv
clear
fc
sera
mice
administ
either
scfv
clear
fc
alon
moreov
efficaci
clearanc
profil
mixtur
neutral
dose
scfv
combin
antitag
clear
fc
compar
polyclon
antitoxin
serum
schemat
illustr
fcmediat
clearanc
antibodytoxin
complex
via
multimer
antibodi
decor
toxin
clearanc
ic
occur
via
fcr
cr
pathway
involv
antibodi
fc
lowaffin
fcr
resid
macrophag
bind
antibodyantigen
complex
high
avid
bind
monomer
antibodyantigen
ic
detect
affin
addit
larger
iggtoxin
ic
much
effici
clear
bloodstream
thu
mab
cocktail
might
mimic
polyclon
reaction
form
larg
ic
multipl
fc
toxin
decor
result
substanti
enhanc
antibodytoxin
complex
clearanc
figur
illustr
bind
multipl
fc
high
avid
fcr
b
oppos
low
affin
bind
singl
mab
fc
addit
experi
perform
lab
investig
role
toxin
block
clearanc
determin
antitoxin
efficaci
author
gener
small
kda
stabl
camelid
heavychainonli
ab
vh
vhh
domain
bonta
vhh
use
antitoxin
via
coadministr
recombin
highaffin
antibont
tag
vhh
antitag
clear
fc
author
compar
neutral
nonneutr
bind
vhh
administ
without
clear
fc
evalu
rel
contribut
toxin
block
clearanc
antitoxin
activ
cocktail
three
vhh
contain
one
tag
administ
antitag
clear
fc
insuffici
induc
effici
clearanc
howev
heterodim
consist
two
nonneutr
monomer
vhh
unit
contain
two
tag
instead
one
enabl
simultan
bind
four
fc
domain
toxin
result
toxin
clearanc
dramat
enhanc
protect
mice
virtual
protect
absenc
clear
fc
complet
protect
bonta
furthermor
comparison
antitoxin
efficaci
neutral
nonneutr
vhh
agent
presenc
absenc
antitag
clear
fc
reveal
neutral
vhh
highli
effect
absenc
clearanc
improv
presenc
clear
fc
wherea
nonneutr
vhh
depend
clear
fc
effici
neutral
similar
techniqu
util
vhhbase
neutral
agent
vna
clear
fc
agent
demonstr
effect
stx
tremblay
et
al
show
coadministr
vna
antitag
fc
substanti
increas
prevent
death
kidney
damag
mice
follow
challeng
howev
recent
conduct
antiricin
studi
contradict
result
obtain
vanc
et
al
show
one
hand
addit
clear
fc
agent
doubletag
vhh
heterodim
enabl
four
fc
molecul
decor
toxin
molecul
significantli
increas
protect
mice
ricin
toxic
like
via
promot
toxin
clearanc
hand
presenc
absenc
antitag
clear
fc
link
high
affin
heterodim
consist
two
nonneutr
vhh
afford
mice
protect
ricin
challeng
ricin
toxic
cell
type
preferenti
target
macrophag
includ
kuppfer
cell
liver
author
postul
acceler
clearanc
ricin
absenc
inhibit
function
ricin
domain
may
improv
clinic
result
might
even
enhanc
toxic
signific
fc
valenc
toxin
clearanc
circul
recent
shown
use
red
blood
cell
rbc
mediat
toxin
sequestr
opson
particul
pathogen
antibodi
complement
lead
bind
complement
specif
primat
erythrocyt
immun
adher
may
prevent
pathogen
leav
bloodstream
facilit
destruct
liver
macrophag
ronald
taylor
colleagu
use
mab
specif
crosslink
pathogen
specif
mab
gener
heteropolym
hp
bind
wide
rang
substrat
primat
erythrocyt
imit
natur
clearanc
mechan
substrat
bound
erythrocyt
way
fc
receptor
phagocyt
cell
engag
erythrocytebound
complex
remov
proteolysi
entir
immun
complex
intern
spare
erythrocyt
hp
methodolog
recent
appli
sharma
et
al
use
bont
model
system
attempt
enhanc
toxin
rather
particul
pathogen
neutral
convert
pair
bont
specif
mab
hp
test
transgen
mice
express
human
rbc
membran
author
report
two
hp
given
combin
greater
potenc
unmodifi
mab
capabl
neutral
bonta
ic
form
hp
unmodifi
mab
less
potent
form
two
hp
addit
periton
macrophag
intern
bont
better
bound
two
hp
rather
hp
mab
mab
mab
combin
independ
whether
hp
pair
contain
nonbind
control
mab
may
indic
enhanc
bont
clearanc
blood
circul
fix
tissu
macrophag
attribut
opson
multipl
fc
domain
hp
complex
current
modern
biotechnolog
advanc
enabl
manufactur
unlimit
suppli
human
human
mab
well
monospecif
biopharmaceut
display
exquisit
specif
unpreced
affin
lifethreaten
toxin
exhibit
low
risk
immunogen
low
batchtobatch
variabl
long
serum
halflif
month
reduc
frequenc
drug
administr
characterist
highli
valuabl
advantag
compar
pabbas
prepar
howev
antigen
variabl
toxin
pathogen
gener
rel
low
efficaci
individu
antitoxin
mab
limit
util
therapeut
one
ration
solut
overcom
limit
would
combin
mab
therapeut
cocktail
mimic
safe
polyclon
respons
recent
option
difficult
implement
due
regulatori
cost
concern
nevertheless
effort
recent
year
produc
effect
mab
cocktail
postexposur
rabi
botulinum
prophylaxi
establish
import
preced
increas
relev
use
mab
combin
toxin
infecti
diseas
mani
studi
shown
tabl
differ
combin
mab
variou
toxin
infecti
agent
inde
exhibit
enhanc
efficaci
mani
case
enhanc
synergist
occasion
exceed
efficaci
pabbas
prepar
gener
use
review
describ
bodi
evid
support
three
potenti
mechan
underli
synergist
neutral
mab
combin
simultan
bind
interf
mab
multipl
function
site
toxin
facilit
signific
blockad
two
essenti
epitop
react
target
cell
thu
dramat
reduc
potenc
toxin
dramat
increas
affin
combin
mab
compar
mab
compon
correl
neutral
fcmediat
clearanc
antibodytoxin
ic
serum
enhanc
multimer
antibodi
fc
decor
toxin
plausibl
three
mechan
complement
combin
mechan
mediat
enhanc
cooper
activ
mab
cocktail
mechan
may
also
clarifi
contribut
individu
nonneutr
mab
synergist
neutral
mab
cocktail
phenomenon
observ
previou
studi
lab
other
synerg
facilit
increas
valenc
fc
molecul
decor
toxin
therebi
enhanc
toxin
clearanc
target
critic
number
epitop
increas
avid
mab
cocktail
via
interact
two
mechan
one
conclus
may
screen
toxinneutr
mab
involv
highaffin
mab
combin
avoid
overlook
mab
individu
display
low
neutral
activ
mab
cocktailbas
drug
display
enhanc
neutral
efficaci
significantli
lower
amount
drug
administ
comparison
efficaci
singl
monoclon
antibodi
like
reduc
cost
side
effect
synergist
activ
mab
combin
may
depend
presenc
fc
fc
isotyp
thu
vitro
assess
neutral
capac
mab
combin
might
fulli
reflect
vivo
potenc
moreov
evalu
mab
certain
anim
origin
might
exert
full
potenc
due
interspeci
varianc
fcr
cr
therefor
special
care
taken
select
anim
model
evalu
synergist
effect
mab
combin
understand
mechan
underli
synergist
neutral
crucial
combin
mab
form
potent
antibodi
cocktail
futur
experi
focu
develop
analyt
tool
enabl
investig
mechan
tempt
specul
control
enhanc
neutral
might
becom
feasibl
via
ration
select
combin
mab
eran
diamant
amram
torgeman
eyal
ozeri
ran
zichel
conceiv
review
wrote
manuscript
